Xeris Biopharma (XERS) officer sells 16,667 shares in Rule 10b5-1 trades

Rhea-AI Filing Summary

Xeris Biopharma Holdings, Inc. reported that company officer Beth Hecht executed two open-market sales of its common stock under a pre-established Rule 10b5-1 trading plan. She sold a total of 16,667 shares on March 2, 2026, at prices including $6.2401 and $7.06 per share, and held 1,226,507 shares afterward.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hecht Beth

(Last) (First) (Middle)

C/O XERIS BIOPHARMA HOLDINGS, INC.

1375 WEST FULTON STREET, SUITE 1300

(Street)

CHICAGO IL 60607

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Xeris Biopharma Holdings, Inc. [ XERS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		S(1)		16,567	D	$6.2401(2)	1,226,607	D
Common Stock	03/02/2026		S(1)		100	D	$7.06	1,226,507	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.920 to $6.910, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Remarks:

Chief Legal Officer and Corporate Secretary

	/s/ Beth Hecht	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did XERS disclose for Beth Hecht?

Xeris Biopharma disclosed that company officer Beth Hecht sold common stock in two open-market transactions. The trades occurred on March 2, 2026, under a Rule 10b5-1 trading plan, reflecting a pre-arranged schedule rather than discretionary same-day trading decisions.

How many Xeris Biopharma (XERS) shares did Beth Hecht sell?

Beth Hecht sold a total of 16,667 shares of Xeris Biopharma common stock. The Form 4 shows one sale of 16,567 shares and a second sale of 100 shares, both executed on March 2, 2026, as part of her trading activity.

At what prices did Beth Hecht sell XERS shares?

Beth Hecht’s reported sales included 16,567 shares at $6.2401 per share and 100 shares at $7.06 per share. A footnote notes that certain shares were sold in multiple trades, with prices within a specified range around these weighted-average values.

Does Beth Hecht still hold Xeris Biopharma shares after these sales?

Yes. After completing the reported March 2, 2026 transactions, Beth Hecht directly owned 1,226,507 shares of Xeris Biopharma common stock. This post-transaction figure reflects her remaining direct holdings following the total sale of 16,667 shares disclosed in the Form 4.

Were Beth Hecht’s XERS stock sales under a Rule 10b5-1 plan?

Yes. A footnote states the transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by Beth Hecht. Such plans allow insiders to prearrange stock sales, providing structure for trades that occur over time under predetermined instructions.